IAM Life Sciences 2018

The key IP issues that entities operating in the pharmaceutical and biotechnology industries may confront as they develop and roll out their business strategies.


Start-ups in life sciences – optimising IP value

Brann AB

Patents and other intellectual property are increasingly important in life sciences and key drivers in market dynamics.
Annika Kilander, Camilla Lidén and Gerald Pettersson

Sprycel – new plausibility threshold for life sciences patents?


The Technical Board of Appeal of the European Patent Office (EPO) decision (February 1 2017) upholding the revocation of Bristol-Myer Squibb’s (BMS) European Patent 1169038 for lack of inventive step came as a shock and a surprise for many in the pharmaceutical sector.
Arwed Burrichter, Natalie Kirchhofer and Romina Kühnle

Trends in pharma patent litigation in Russia

Gorodissky & Partners

During recent years the number of patent infringement cases in the pharmaceutical field has increased significantly.
Ilya Goryachev

Patents and trademarks in Malaysia’s life sciences sector

Henry Goh & Co Sdn Bhd

The patent infringement case of Merck Sharp & Dohme Corp v Hovid Bhd ([2017] MLJU 77, January 6 2017; Suit 22IP-72-12/2014) centred around Malaysian Patent MY-118194-A (the ‘194 patent).
Eng Leong Lim and Yen Yen Oon

How European law affects national regulation of life sciences patents

JWP Patent and Trademark Attorneys

As is the case with any office or court of a country party to the European Patent Convention (EPC) deciding on the revocation of a patent, the Polish Patent Office (PPO) faces a major challenge whenever local regulations do not fully overlap with EPC regulations.
Piotr Godlewski and Helena Gajek

Overview of regulatory reform in China

Liu, Shen & Associates

With the development of the economy, China has become the second largest pharmaceuticals market in the world.
Lili Cao and Zongliang (Stephen) Zou

Undisclosed disclaimers in Europe – regulations reloaded

Maikowski & Ninnemann Patentanwälte Partnerschaft mbB

In most cases, during the examination of a patent application before grant or during opposition proceedings of a patent after grant, the applicant must deal with prior art documents cited by the examiner or opponents against the patentability of the claims.
Matthias Hoffmann and Fabian Sokolowski

Medical use of cannabinoids – analysis of Brazilian authorities’ position

Montaury Pimenta, Machado & Vieira de Mello

The medical use of cannabidiol – one of several cannabinoids found in plants belonging to the cannabis genus – has increased significantly over the past two decades.
Gabriela Salerno

Protecting second medical use – opportunities and pitfalls


Innovators continue to develop drugs to further understand how to optimise the use of known drugs.
Caroline Pallard

Modernisation of international treaties – impact on life sciences


Mexico’s statutory IP law, the Industrial Property Law (enacted in 1991 and modified in 1994), resulted from the North American Free Trade Agreement (NAFTA) negotiations with the United States and Canada and the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs).
Alejandro Luna F, Erwin Cruz and Rommy Morales

SPC system – simple, transparent and easy to apply?

Powell Gilbert LLP

Patent term extensions for human and veterinary medicaments and plant protection products are available in Europe through the grant of supplementary protection certificates (SPCs), which effectively extend the term of a granted patent in relation to a particular product that is the subject of a marketing authorisation.
Peter Damerell, Ayesha Raghib and William Hillson

Patenting personalised medicines in Europe

Weickmann & Weickmann

The established approach to drug development is based on the assumption that all patients with a particular condition respond similarly to a given drug.
Christian Heubeck and Wolfgang Weiss


Register for more free content

  • Read more IAM blogs and articles
  • Receive the editor's weekly review by email
Register now  
Issue 91